Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 03:56pm CET

JOHANNESBURG - Aspen yesterday welcomed the Competition Commission's decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commission’s initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts “due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable”.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. “In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany,” the commission said.

“It is, therefore, unlikely that the price charged by Equity could pass the test for excessive pricing.” The commission, however, alleged that Roche and Genentech had engaged in excessive pricing, price discrimination and exclusionary conduct in the provision of breast cancer medicine in South Africa, adding that breast cancer treatment was unaffordable in South Africa.

The commission said investigations on Pfizer for excessive pricing of lung cancer medication in South Africa would continue. The drug maker was the only provider of a lung cancer treatment medication, known asXalkori (crizotinib), in South Africa. The body also alleged that lung cancer treatment in South Africa was unaffordable.

Aspen shares fell 0.01 percent on the JSE yesterday to close at R304.75 a share.


(c) Cape Community 1999 - 2017 Independent Newspapers (Pty) Limited. All rights strictly reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
09:17a ROCHE : EU Approves Roche`s OCREVUS for Relapsing Forms of MS
01/15 BIOGEN : Roche's Ocrevus receives EU approval for MS
01/13 ROCHE : Genentech beefs up its PD-L1 combo pipeline, signing the dont eat me spe..
01/13 ROCHE : Roches Ocrevus MS drug approved in EU
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SYNDAX PHARMACEUTICALS : announces further entinostat collaboration with Roche
01/12 ROCHE : Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination f..
01/12 ROCHE : OCREVUS (ocrelizumab) approved in the European Union for relapsing forms..
01/12 ROCHE : Niger to Screen 1 Million Cancer Patients, Treat 20 Diagnosed Cases Annu..
More news
News from SeekingAlpha
01/15 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Roche's MS Win, Aradigm FDA Panel Woes, A..
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
01/12 EC OKs Roche's MS med Ocrevus
01/11 YOUR DAILY PHARMA SCOOP : Roche Highlights Pipeline, GenSight Gets Nod To Start ..
01/10 Roche Holding ADR (RHHBY) Presents At 36th Annual J.P. Morgan Healthcare Conf..
Financials ( CHF)
Sales 2017 53 552 M
EBIT 2017 18 174 M
Net income 2017 11 159 M
Debt 2017 9 887 M
Yield 2017 3,52%
P/E ratio 2017 18,24
P/E ratio 2018 16,72
EV / Sales 2017 4,11x
EV / Sales 2018 3,88x
Capitalization 210 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 274  CHF
Spread / Average Target 12%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-0.28%218 350
JOHNSON & JOHNSON4.32%388 981
NOVARTIS1.80%224 968
PFIZER0.88%217 923
AMGEN6.41%134 322